Dear Participating Pharmaceutical Manufacturer:

Thank you for your participation in the National Medicaid Pooling Initiative ("NMPI") administered by Prime Therapeutics, on behalf of our state Medicaid clients. This is year 2 in the 3-year NMPI contract cycle. New bids as well as enhanced offers will become effective on April 1, 2027 and run through March 31, 2029.

NMPI is the largest multistate purchasing pool with over 17 million lives and 13 participating Medicaid programs, which include Alaska, Arkansas, District of Columbia, Michigan, Minnesota, Montana, Nevada, New Hampshire, New York, North Carolina, Rhode Island, South Carolina, and Virginia. Manufacturers cannot exclude any Participating State as part of their bid submission and offers must apply to all indications.

Important Note!

- As this is the second year of the NMPI cycle, this solicitation is limited to ENHANCEMENTS on existing offers from year 1 or NEW offers.
- Please do not resubmit offers from last year if they remain unchanged. Only submit offers that are new or have been enhanced since last year's solicitation; unchanged offers do not require resubmission.
- Manufacturers are required to use **simple**, **direct**, and **clear** offer language that Participating Medicaid States, invoicing teams, operational teams, and others can understand (do not include company abbreviations for drugs or for drug classes).
  Non-compliant language will be rejected.
- Please refer to the Manufacturer Offer Language Guidance attachment for examples of acceptable offer language.
- Product count is determined by the products listed on Schedule 1 relative to positioned offers with the exception of biosimilars and biobetters, which we consider to be generic and do not count as part of positioned offers for reference drugs. An exception will be made for biosimilar manufacturers submitting positioned offers.

Schedule 1 defines competitive therapeutic classes and manufacturers are encouraged to bid accordingly. Schedule 1 has been updated for this bid solicitation. In addition, we

include an optional bid matrix for drugs not included in Schedule 1 to allow manufacturers to submit access offers in non-competitive categories. **For manufacturers that have branded products with loss of exclusivity, we welcome the opportunity to evaluate an offer for the benefit of our states**.

Finally, the NMPI Contract template is being revised with non-substantive changes and will be provided to you upon approval by all states.

Instructions and relevant documents for the submission of supplemental rebate bids are attached for your reference only.

1. NMPI Supplemental Drug Rebate Agreement (FOR REFERENCE ONLY)
2. Attachment A – Participation Agreement (FOR REFERENCE ONLY)
3. Attachment A-1 – List of Non-Medicaid Programs (FOR REFERENCE ONLY)
4. Attachment A-2 – Attestation for Medicaid MCOs (FOR REFERENCE ONLY)
5. Attachment B – Catalogue of NMPI Participating States (FOR REFERENCE ONLY)
6. Schedule 1: Product Category Listing (FOR REFERENCE ONLY)
7. Schedule 2: PDL Matrix Form (FOR REFERENCE ONLY)
8. Schedule 3: Supplemental Rebate Calculation (FOR REFERENCE ONLY)

<u>Please note the following:</u>

1. Submit the NMPI Supplemental Rebate Offer Form through the Secure FTP site: (https://secureftp.providersynergies.com/).
2. The attached 2027 Schedule 2 PDL Matrix Form is for reference only. In December, Schedule 2 will be generated by Prime Therapeutics and sent to manufacturers for execution.
3. An access bid (one of many) is required, and positioned offers are encouraged.
4. Additional offer language may be submitted directly in the Offer Form, provided it is simple, direct, and clear, as stated above.
5. Offer language on the form is limited to 220 characters.

Manufacturers are reminded that all pricing submitted will be considered "**BEST and**

FINAL." As stated on the offer form, submitted offers are binding. Final pricing (submitted through the FTP site) is due to Prime Therapeutics by close of business on **Thursday, November 19, 2026**.

If you did not receive the attachments included in this e-mail notification, all documents may be obtained from our web site at: https://www.primetherapeutics.com/en/nmpi.

- For detailed written instructions on how to access and upload your Offer Form to the Secure FTP site, please contact William Trivett (william.trivett@primetherapeutics.com). Requests for new usernames and passwords, or requests to re-set existing usernames and passwords may also be submitted by e-mail to Nicole Robinson (nicole.robinson@primetherapeutics.com). Usernames and passwords will not be provided over the telephone.
- Please direct all other questions concerning NMPI to Prime PDL Leadership (primepdlleadership@primetherapeutics.com).

Thank you.